A national nonprofit organization that provides innovative lifestyle empowerment programs for people with MS and their support partners.
A professional organization for MS healthcare providers and researchers in North America.
An international organization focusing on the needs of nurses involved with MS care, education, research, and advocacy.
A national nonprofit organization dedicated to enriching the quality of life for people affected by MS.
A free self-care application for the MS community from the Multiple Sclerosis Association of America.
A national nonprofit organization that helps people with MS maintain their health and well-being through programming and support to keep them self-sufficient.
An international nonprofit established to link the activities of national MS societies around the world.
A national nonprofit organization with a 50-state network of chapters dedicated to funding research, advocacy, facilitating professional education, and providing programs and support for people affected by MS.
A.D.A.M. Medical Encyclopedia. Multiple sclerosis.
www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001747/. Accessed October 4, 2012.
Achiron A, Gabbay U, Gilad R, et al. Intravenous immunoglobulin treatment in multiple sclerosis. Neurology. 1998;50:398-402.
American Academy of Neurology. Assessment of Plasmapheresis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 1996;47:840-843.
American Association of Neuroscience Nurses-Association of Rehabilitation Nurses. Nursing Management of the Patient with Multiple Sclerosis. AANN and ARN Clinical Practice Guideline Series. Updated 2011. www.aann.org/uploads/AANN-ARN-IOMSN_MS_Guideline_FINAL.pdf. Accessed January 10, 2013.
Artemiadis AK, Anagnostouli MC, Alexopoulos EC. Stress as a risk factor for multiple sclerosis onset or relapse: a systematic review. Neuroepidemiol. 2011;36:109-120.
Brodkey MB, Ben-Zacharia AB, Reardon JD. Living well with multiple sclerosis. Am J Nurs. 2011;111:40-48.
Catania A. The melanocortin system in leukocyte biology. J Leukoc Biol. 2007;81:383-392.
Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A. Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011;76:294-300.
Encyclopedia Britannica online. Brain. www.britannica.com/EBchecked/topic/77269/brain. Accessed November 9, 2012.
Encyclopedia Britannica online. The nerve cell. www.britannica.com/EBchecked/topic/409665/nervous-system/75817/The-nerve-cell. Accessed November 9, 2012.
Houghton Mifflin Company. The American Heritage Medical Dictionary. http://medical-dictionary.thefreedictionary.com/Uhthoff's+phenomenon. Accessed November 7, 2012.
Katz U, Kishner I, Magalashvili D, Shoenfeld Y, Achiron A. Long term safety of IVIg therapy in multiple sclerosis: 10 years experience. Autoimmunity. 2006;39:513-517.
Köpke S, Heesen C, Kasper J, Mühlhauser I. Steroid treatment for relapses in multiple sclerosis – the evidence urges shared decision-making. Acta Neurol Scand. 2004;110:1-5.
MacLean R. Multiple sclerosis: understanding a complex neurological condition. Nursing Standard. 2010;24:50-56.
Merriam-Webster Online Medical Dictionary. http://mw1.merriam-webster.com/medical/. Accessed November 8, 2012.
Merriam-Webster Word Central. http://www.wordcentral.com/. Accessed November 8, 2012.
National Clinical Advisory Board of the National Multiple Sclerosis Society. Changing therapy in relapsing multiple sclerosis: considerations and recommendations of a Task Force of the National Multiple Sclerosis Society. Expert Opinion Paper: Treatment Recommendations for Physicians. www.nationalmssociety.org/download.aspx?id=129. Updated 2004. Accessed January 11, 2013.
National Institutes of Neurological Disorders and Stroke. Multiple sclerosis: hope through research.
www.ninds.nih.gov/disorders/multiple_sclerosis/detail_multiple_sclerosis.htm. Accessed October 4, 2012.
Nicholas R, Giannetti P, Alsanousi A, Friede E, Muraro PA. Development of oral immunomodulatory agents in the management of multiple sclerosis. Drug Des Devel Ther. 2011;5:255-274.
Oliver BJ. Primary care management of fatigue and relapses in RRMS. The Nurse Pract. 2009;34:10-14.
Rejdak K, Jackson S, Giovannoni G. Multiple sclerosis: a practical overview for clinicians. Br Med Bullet. 2010;95:79-104.
Rolak LA. National Multiple Sclerosis Society. The basic facts: the history of MS. www.nationalmssociety.org/download.aspx?id=32. Updated 2009.Accessed November 8, 2012.
Ross AP, Halper J, Harris CJ. Assessing relapsing and response to relapse treatment in patients with multiple sclerosis. A nursing perspective. [Consensus Statement] Int J MS Care. 2012;14:148-159.
Schapiro RT. Managing the Symptoms of Multiple Sclerosis. 5th ed. New York, NY: Demos Medical Publishing LLC; 2007.
Thompson HJ, Mauk KL, Ross AP, et al. Nursing management of the patient with multiple sclerosis. AANN and ARN Clinical Practice Guidelines Series. www.aann.org/pubs/content/guidelines.html. Accessed October 8, 2012.
Thrower BW. Relapse management in multiple sclerosis. Neurologist. 2009;15:1-5.
U.S. National Institutes of Health. ClinicalTrials.gov search engine. http://clinicaltrials.gov/. Updated January 11, 2013. Accessed January 11, 2013.
Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999;46:878-886.
Zindler E, Zipp F. Neuronal injury in chronic CNS inflammation. Best Pract Res Clin Anaesthesiol. 2010;24:551-562.